NSC12

NSC12 is a small molecule described as an extracellular trap for fibroblast growth factor 2 (FGF2). It binds to FGF2 and interferes with its interaction with the fibroblast growth factor receptor 1 (FGFR1), thereby inhibiting FGF/FGFR signaling. This mechanism disrupts pathways critical for cancer cell proliferation and survival, particularly in malignancies dependent on FGF stimulation such as multiple myeloma. Preclinical studies have demonstrated that NSC12 exhibits antitumor activity by blocking the proliferation of multiple myeloma cells both in vitro and in vivo. The compound was initially developed at the University of Parma[1][2][6].